All In Biotech

Free tool

FAERS Monitor: Myobloc

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 103846 or its brand name (Myobloc, Botulinum Toxin Type B). Reports on generic versions are filed under their own applications.

Reports

328

Serious

188

57% of reports

Hospitalization

65

Death reported

58

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • dry mouth46
  • dysphagia43
  • death42
  • product use in unapproved indication34
  • drug ineffective30
  • headache23
  • vision blurred22
  • off label use21
  • dyspnoea15
  • constipation14
  • nausea14
  • neck pain14
  • pain14
  • asthenia13
  • fatigue12

Reports by year received

View as table
YearReports
200437
20055
200613
200711
20088
20097
20105
20111
20123
20134
20143
20157
20166
201716
201820
201915
202016
202123
202228
202324
202429
202532
202615

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,831 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
dry mouthSignal4636.427.81,552
dysphagiaSignal4329.122.01,142
neck painSignal1416.19.6183
vision blurredSignal2210.36.9176
product use in unapproved indicationSignal348.86.4230
constipationSignal144.12.530
deathSignal423.12.461
headacheSignal232.41.617
astheniaSignal132.21.38
dyspnoea151.71.04
off label use211.51.04
pain141.50.92
drug ineffective301.51.04
nausea141.10.70
fatigue121.00.60

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.